Posted by Michael Wonder on 25 Jan 2017
EAMS scientific opinion: atezolizumab for locally advanced or metastatic urothelial carcinoma
23 January 2017 - The MHRA has published its EAMS scientific opinion for atezolizumab to treat locally advanced or metastatic urothelial carcinoma.
The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising new unlicensed medicines to UK patients that have a high unmet clinical need. The MHRA scientific opinion provides benefit and risk information to doctors who may wish to prescribe the unlicensed medicine under their own responsibility.
